Q BioMed, Inc. operates as a biomedical acceleration and development company. It focuses on acquiring, licensing, and providing resources to life sciences and healthcare companies. Its products include Strontium 89, QBM-001, Uttroside-B, and MAN 01. The company was founded by Enrique Navas on November 22, 2013 and is headquartered in New York, NY.
Company profile
Ticker
QBIO
Exchange
Website
CEO
Denis D. Corin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ISMO Tech Solutions, Inc.
SEC CIK
QBIO stock data
Latest filings (excl ownership)
UPLOAD
Letter from SEC
7 Sep 23
UPLOAD
Letter from SEC
10 Aug 23
UPLOAD
Letter from SEC
3 Jul 23
8-K
Other Events
16 Jun 23
10-Q
2023 Q1
Quarterly report
16 Jun 23
8-K
Other Events
26 May 23
10-K
2022 FY
Annual report
26 May 23
NT 10-K
Notice of late annual filing
1 Mar 23
DEF 14C
Information statement
7 Dec 22
Latest ownership filings
SC 13G/A
YA II PN, Ltd.
3 Jan 23
SC 13G/A
Jatwes Ari
1 Jun 22
4
William S Rosenstadt
31 May 22
4
Denis Corin
31 May 22
SC 13G/A
YA II PN, Ltd.
11 Jan 22
144
Notice of proposed sale of securities
22 Apr 21
4
William S Rosenstadt
26 Feb 21
SC 13G/A
YA II PN, Ltd.
5 Feb 21
4
Denis Corin
19 Nov 20
4
William S Rosenstadt
19 Nov 20
Financial summary
Quarter (USD) | Feb 23 | Nov 22 | Aug 22 | May 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 22 | Nov 21 | Nov 20 | Nov 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 49.97 k | 49.97 k | 49.97 k | 49.97 k | 49.97 k | 49.97 k |
Cash burn (monthly) | 98.01 k | 7.27 k | 148.34 k | 227.18 k | 46.06 k | (no burn) |
Cash used (since last report) | 1.28 mm | 94.59 k | 1.93 mm | 2.96 mm | 599.52 k | n/a |
Cash remaining | -1.23 mm | -44.62 k | -1.88 mm | -2.91 mm | -549.55 k | n/a |
Runway (months of cash) | -12.5 | -6.1 | -12.7 | -12.8 | -11.9 | n/a |
Institutional ownership, Q3 2023
7.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 10.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
YA II PN | 10.21 mm | $0.00 |